Activation of human complement by immunoglobulin G antigranulocyte antibody.
The ability of antigranulocyte antibody to fix the third component of complement (C3) to the granulocyte surface was investigated by an assay that quantitates the binding of monoclonal anti-C3 antibody to paraformaldehyde-fixed cells preincubated with Felty's syndrome serum in the presence of human complement. The sera from 7 of 13 patients with Felty's syndrome bound two to three times as much C3 to granulocytes as sera from patients with uncomplicated rheumatoid arthritis. The complement-activating ability of Felty's syndrome serum seemed to reside in the monomeric IgG-containing serum fraction. For those sera capable of activating complement, the amount of C3 fixed to granulocytes was proportional to the amount of granulocyte-binding IgG present in the serum. Thus, complement fixation appeared to be a consequence of the binding of antigranulocyte antibody to the cell surface. These studies suggest a role for complement-mediated injury in the pathophysiology of immune granulocytopenia, as has been demonstrated for immune hemolytic anemia and immune thrombocytopenia.
D001172:Arthritis, Rheumatoid / Q000276:immunology; D001323:Autoantibodies; D003167:Complement Activation; D003176:Complement C3 / Q000276:immunology*; D005258:Felty Syndrome / Q000276:immunology*; D006098:Granulocytes / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology
D001323:Autoantibodies; D003176:Complement C3; D007074:Immunoglobulin G